Pharma news - Ataxia UK

Pharma news

Alterity Therapeutics announces positive results from its phase 2 trial of the drug ATH434 in MSA

Cerebellar ataxia, Research News, Uncategorised /

On January 30th 2025, the pharmaceutical company Alterity Therapeutics announced positive data from their phase 2 placebo-controlled trial in early-stage MSA. MSA is a progressive neurological condition leading to impaired […]

Alterity Therapeutics announces positive results from its phase 2 trial of the drug ATH434 in MSA Read More »

Large magnifying glass on light blue background

Larimar Therapeutics announces progress of the Nomlabofusp (CTI-1601) trial for Friedreich’s ataxia

1 Comment / Friedreich's ataxia, Friedreich's ataxia pharma news, Research News /

Following clearance by the US drug regulatory body the Food and Drug Administration (FDA) in July 2023, the pharmaceutical company Larimar Therapeutics has completed full enrolment and dosing of the

Larimar Therapeutics announces progress of the Nomlabofusp (CTI-1601) trial for Friedreich’s ataxia Read More »

Cart
Checkout - £0.00
  • 0
  • 1
Scroll to Top